Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzamidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.94 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.94 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.94 |
| ▸ | C1S | P09871 | 2/20 | 0.94 |
| ▸ | RECQL | P46063 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.94 |
| ▸ | F2 | P00734 | 4/20 | 0.94 |
| ▸ | F10 | P00742 | 1/20 | 0.94 |
| ▸ | F12 | P00748 | 1/20 | 0.94 |
| ▸ | F7 | P08709 | 1/20 | 0.94 |
| ▸ | F3 | P13726 | 1/20 | 0.94 |
| ▸ | PKM | P14618 | 1/20 | 0.94 |
| ▸ | WDR5 | P61964 | 1/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PLG | P00747 | 1/20 | 0.56 |
| ▸ | PLAU | P00749 | 2/20 | 0.55 |
| ▸ | MASP2 | O00187 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamidine SCHEMBL29191424 | 1.00 | BLM (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL6861235 | 1.00 | BLM (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL23235801 | 1.00 | BLM (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL27303891 | 1.00 | BLM (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL29191425 | 0.97 | BLM (0.94) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL596593 | 0.97 | PRSS1 (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL9040332 | 0.97 | PRSS1 (1.00) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL28224057 | 0.97 | BLM (0.94) | BLMPRSS1PRSS3PRSS2C1S | |
| Benzamidine SCHEMBL28147189 | 0.97 | BLM (0.94) | BLMPRSS1PRSS3PRSS2C1S | |
| SCHEMBL18557033 | 0.97 | F2 (1.00) | BLMPRSS1PRSS3PRSS2C1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6102 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388896-A1 | COMPOSITION AND METHODS FOR TRANSGENE INSERTION | CELYNTRA THERAPEUTICS SA (BE) | 2025-12-25 | — | — | US | claimed |
| EP-4652187-A1 | CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS | AbbVie Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| EP-4652186-A2 | CLOSTRIDIUM BOTULINUM SEROTYPE A NEUROTOXIN (BONT/A) SEQUENCE VARIANTS | AbbVie Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| EP-4631514-A1 | ORAL POLYPEPTIDE COMPOSITION AND USE THEREOF | Hefei Tianhui Biotech Co., Ltd. (CN) | 2025-10-15 | — | — | EP | claimed |
| US-20250281579-A1 | Methods and Compositions for Oral Administration of Proteins | ORAMED PHARMACEUTICALS INC (IL) | 2025-09-11 | — | — | US | claimed |
| CN-120166906-A | Two-dimensional/three-dimensional perovskite heterojunction based on amidino cation and application of perovskite heterojunction in solar cell | 西安交通大学 | 2025-06-17 | — | — | CN | claimed |
| CN-120166900-A | Perovskite solar cell based on binary spacers and single crystals and preparation method | 西安交通大学 | 2025-06-17 | — | — | CN | claimed |
| CN-120054595-A | Modified Y-type molecular sieve, preparation method thereof and hydrocracking catalyst | 中国石油天然气股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120054596-A | Modified Y-type molecular sieve, preparation method thereof and hydrocracking catalyst | 中国石油天然气股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120054597-A | Modified Y-type molecular sieve and preparation method and application thereof | 中国石油天然气股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| EP-0159564-B1 | METHOD FOR DETERMINING LIPID BOUND SIALIC ACID IN PLASMA | DIANON SYSTEMS, INC. (US) | 1990-05-16 | — | — | EP | claimed |
| EP-0159563-B1 | METHOD FOR DETERMINING LIPID BOUND SIALIC ACID IN WHOLE BLOOD | DIANON SYSTEMS, INC. (US) | 1990-04-25 | — | — | EP | claimed |
| US-4786726-A | Factor IX therapeutic blood product, means and methods of preparing same | BLOOD SYSTEMS, INC. (US) | 1988-11-22 | — | — | US | claimed |
| EP-0280470-A1 | Method of purifying recombinant pres-1/S-2/S hepatitis B antigen from yeast | MERCK & CO. INC. (US) | 1988-08-31 | — | — | EP | claimed |
| US-4748128-A | CANCER DIAGNOSIS | DIANON SYSTEMS, INC. (US) | 1988-05-31 | — | — | US | claimed |
| US-4701418-A | Method for determining lipid bound sialic acid in whole blood | DIANON SYSTEMS, INC. (US) | 1987-10-20 | — | — | US | claimed |
| EP-0229026-A2 | Therapeutic blood product, means and methods of preparing same | Blood Systems Inc, an Arizona not-for-profit corporation (US) | 1987-07-15 | — | — | EP | claimed |
| US-4638050-A | PLACENTA, WASHIG, GRINDING, PRECIPITATION, EXTRACTION, ELUTION, ANTICOAGULANTS | KOWA CO., LTD. (JP) | 1987-01-20 | — | — | US | claimed |
| EP-0159563-A1 | Method for determining lipid bound sialic acid in whole blood | DIANON SYSTEMS, INC. (US) | 1985-10-30 | — | — | EP | claimed |
| US-3988364-A | ANTITUSSIVE AGENTS | TOYO JOZO KABUSHIKI KAISHA (JA) | 1976-10-26 | — | — | US | claimed |